Literature DB >> 17413317

Plasma Abeta levels do not reflect brain Abeta levels.

Stefanie H Freeman1, Susan Raju, Bradley T Hyman, Matthew P Frosch, Michael C Irizarry.   

Abstract

Cerebral accumulation of amyloid beta protein (Abeta) is characteristic of Alzheimer disease (AD). Abeta can be detected in cerebrospinal fluid and in plasma. Although plasma Abeta has been proposed as a marker of risk of AD, it is unknown how plasma levels relate to neuropathologic levels. We compared plasma levels of Abeta40 and Abeta42 obtained during life with biochemical and pathologic levels in frontal and temporal neocortex in 25 individuals (17 AD, 3 control, and 5 non-AD dementia) who died a median of 1 year after blood collection. Plasma levels of Abeta40 and Abeta42 were not associated with any of the brain measures, even after adjusting for age and interval between plasma collection and death. The APOE epsilon4 allele may modify the relationship between plasma Abeta42 and formic acid-extractable Abeta42, with an inverse correlation in APOE epsilon4 carriers and a positive correlation in those lacking APOE epsilon4. We conclude that plasma levels of Abeta40 and Abeta42 are not robust correlates of histologic or biochemically assessed amyloid burdens in brain, although the influence of the APOE genotype should be further explored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413317     DOI: 10.1097/NEN.0b013e31803d3ae4

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  22 in total

1.  Soluble amyloid-β levels and late-life depression.

Authors:  Ricardo S Osorio; Tyler Gumb; Nunzio Pomara
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

2.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

Review 3.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

Review 4.  Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.

Authors:  Esther S Oh; Juan C Troncoso; Stina M Fangmark Tucker
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

5.  Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.

Authors:  Joseph J Locascio; Hiroaki Fukumoto; Liang Yap; Teodoro Bottiglieri; John H Growdon; Bradley T Hyman; Michael C Irizarry
Journal:  Arch Neurol       Date:  2008-06

Review 6.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

7.  Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice.

Authors:  Chuanhai Cao; John R Cirrito; Xiaoyang Lin; Li Wang; Lilly Wang; Deborah K Verges; Alexander Dickson; Malgorzata Mamcarz; Chi Zhang; Takashi Mori; Gary W Arendash; David M Holtzman; Huntington Potter
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

8.  Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease.

Authors:  Victor L Villemagne; William E Klunk; Chester A Mathis; Christopher C Rowe; David J Brooks; Bradley T Hyman; Milos D Ikonomovic; Kenji Ishii; Clifford R Jack; William J Jagust; Keith A Johnson; Robert A Koeppe; Val J Lowe; Colin L Masters; Thomas J Montine; John C Morris; Agneta Nordberg; Ronald C Petersen; Eric M Reiman; Dennis J Selkoe; Reisa A Sperling; Koen Van Laere; Michael W Weiner; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

9.  Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD.

Authors:  Pedro Pesini; Virginia Pérez-Grijalba; Inmaculada Monleón; Mercè Boada; Lluís Tárraga; Pablo Martínez-Lage; Itziar San-José; Manuel Sarasa
Journal:  Int J Alzheimers Dis       Date:  2012-08-16

Review 10.  Biological markers for early detection and pharmacological treatment of Alzheimer's disease.

Authors:  Harald Hampel; Karl Broich; Yvonne Hoessler; Johannes Pantel
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.